Anileridine
Clinical data
Trade namesLeritine
AHFS/Drugs.comMonograph
Routes of
administration
Tablets, injection
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding> 95%
MetabolismHepatic
Identifiers
  • Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H28N2O2
Molar mass352.478 g·mol−1
3D model (JSmol)
Melting point83 °C (181 °F)
  • O=C(OCC)C3(c1ccccc1)CCN(CCc2ccc(N)cc2)CC3
  • InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3 checkY
  • Key:LKYQLAWMNBFNJT-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Anileridine (trade name: Leritine) is a synthetic analgesic drug[2] and is a member of the piperidine class of analgesic agents[3] developed by Merck & Co. in the 1950s.[4] It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.

Anileridine is no longer manufactured in the US or Canada.[5] Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate.[6] It is also under international control per UN treaties.

Administration

As tablets or injection.[7]

Pharmacokinetics

Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.[8] It is mostly metabolized by the liver.

See also

References

  1. Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. Orahovats PD, Lehman EG, Chapin EW (January 1957). "Pharmacology of ethyl-1-(4-aminophenethyl)-4-phenylisonipecotate, anileridine, a new potent synthetic analgesic". The Journal of Pharmacology and Experimental Therapeutics. 119 (1): 26–34. PMID 13417056.
  3. Stage JT (August 1957). "Anileridine as an anesthetic agent". The Journal of the Florida Medical Association. Florida Medical Association. 44 (2): 143–5. PMID 13449255.
  4. US 2897204, Frank A Cutler Jr FA, Chemerda JM, "Substituted piperidines and methods for making same", issued 28 July 1959, assigned to Merck and Co Inc
  5. "Discontinued Prescription Drug Products". Canadian Pharmacists' Association. Archived from the original on 19 September 2008. Retrieved 28 July 2008.
  6. "Federal Register Notices: Quotas - 2014". Diversion Control Division, Drug Enforcement Agency. U.S. Department of Justice. 25 August 2014. Archived from the original on 4 March 2016. Retrieved 26 February 2016.
  7. "Pharmaceutical Information - LERITINE". RxMed. Retrieved 16 June 2010.
  8. "Anileridine Consumer Information". MedicineNet. Archived from the original on 28 March 2012. Retrieved 28 July 2008.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.